Clinical Trials Logo

Type 2 Diabetes Mellitus clinical trials

View clinical trials related to Type 2 Diabetes Mellitus.

Filter by:

NCT ID: NCT03707171 Not yet recruiting - Clinical trials for Type 2 Diabetes Mellitus

Effects of Liraglutide on the Cognitive Function in Patients With Type 2 Diabetes Mellitus

Start date: November 1, 2018
Phase: Phase 3
Study type: Interventional

Type 2 diabetes mellitus (T2DM) can impaire cognitive function,the prevalence of Alzheimer's Disease(AD) in T2DM patients is 1.5 to 2.5 times higher than the general population.Cognitive impairment seriously affects the health and quality of life of the elderly. Prevention and treatment measures for cognitive decline in persons with T2DM has not been well studied. Glucagon-like peptide-1 (GLP-1) is a member of an endogenous class of incretin hormones synthesized in intestinal epithelial L-cells.GLP-1 enhances glucose-dependent secretion of insulin,inhibits glucagon secretion, slows gastric emptying and reduces food intake. Liraglutide is a glucagon-like peptide type 1 (GLP-1) analogue. It has been proved that Liraglutide can improve insulin resistance and cognitive function in AD animals. Therefore, it is speculated that Liraglutide may interfere with the occurrence and development of cognitive dysfunction in patients with T2DM. In order to confirm the effects, the investigators conduct an open, prospective, positive controlled study in patients with T2DM. The effect on BMI,waist circumference, hip circumference, waist-to-hip ratio,fasting plasma glucose´╝îglycosylated hemoglobin,blood lipids and cognitive function were measured to explore the effects of liraglutide in patients with T2DM. The overall goal of this study is to explore the effects of liraglutide on the cognitive function in patients with type 2 diabetes mellitus and make further contribution to the improvement of cognitive function.

NCT ID: NCT03705260 Not yet recruiting - Clinical trials for Type 2 Diabetes Mellitus

Quality Initiative to Improve Glucose Control in Type 2 Diabetic Patients

Start date: October 2018
Phase: N/A
Study type: Interventional

The goal of the Twine / University of Michigan Diabetes Quality Improvement Initiative is to improve diabetes care quality using real time feedback with continuous glucose monitoring (CGM) and dietary coaching for lower carbohydrate consumption in a high-risk sub-cohort of outpatients with type 2 diabetes (T2D).

NCT ID: NCT03705195 Recruiting - Clinical trials for Type 2 Diabetes Mellitus

Study of Sulphonylurea Synergy With Incretins

LOGIC
Start date: August 3, 2018
Phase: N/A
Study type: Interventional

The Study of Sulphonylurea Synergy with Incretins (LOGIC) is a Proof-of-Concept Physiological study in the form of two matched isoglycaemic clamps. A matched clamp consists of an of oral glucose tolerance test followed by an isoglycaemic intravenous glucose infusion (IGII). The study will investigate whether there is synergy between a physiological sulphonylurea (SU) stimulus and the incretin effect, causing augmentation of insulin secretion in patients with type 2 diabetes mellitus (T2DM). The study will take place at The Clinical Research Centre at Ninewells Hospital in Dundee over five visits. It will evaluate 20 patients with T2DM on no diabetes therapy, or metformin monotherapy. All participants will undergo two matched clamps. The first matched clamp will be with no intervention. The second intervention matched clamp, low-dose liquid gliclazide will be administered 1-hour prior to each test. The sulphonylurea, Gliclazide, in this this instance will be used as a physiological stimulus and will only be given on two occasions as part of the second matched clamp. The first eight participants will participate in the dose-ranging phase. They will receive either 10mg or 20mg gliclazide as a stimulus to augment the incretin effect. A further twelve participants will then be recruited to complete the study utilising the dose which caused the greatest increment in insulin secretion. LOGIC will also evaluate the cohort for effect of KCNJ11 genotype on physiological response.

NCT ID: NCT03704389 Not yet recruiting - Clinical trials for Type 2 Diabetes Mellitus

Behavioral Economics Applications to Geriatrics Leveraging EHRs

BEAGLE R21
Start date: November 2018
Phase: N/A
Study type: Interventional

The risks and benefits of many diagnostic approaches and treatments differ for older adults compared to middle aged adults. When diagnostic and therapeutic strategies are misapplied to older adults this can lead to increased morbidity and mortality. Well established examples where clinicians do not often follow best practices in the care of older adults include those identified by the American Geriatrics Society for the Choosing Wisely initiative: 1) testing and treatment for asymptomatic bacteriuria, 2) prostate specific antigen testing in older men without prostate cancer, and 3) overuse of insulin or oral hypoglycemics for type 2 diabetes. Clinical decision support nudges, informed by social psychology and delivered via electronic health records (EHRs), are promising strategies to reduce the misuse of services in cases where optimal utilization may not be zero but should be well below current practice. These interventions seek to influence conscious and unconscious drivers of clinical decision making, are low cost to implement and disseminate, and can be incorporated into existing delivery systems. In the R21 phase of this Behavioral Economics Applications to Geriatrics Leveraging EHRs (BEAGLE) study, we will: select EHR delivered nudges to address 3 topics of potential misuse in older adults based on the main psychological drivers of overuse identified in interviews with high-using clinicians; develop and pilot test decision support tools within a health systems' EHR to understand technical feasibility, work flow fit, preliminary impact on clinical outcomes, and clinician acceptability; and develop and validate electronic clinical quality measures of potential overuse/misuse related to the care of older adults.

NCT ID: NCT03704103 Recruiting - Clinical trials for Type 2 Diabetes Mellitus

mHealth Insulin Titration and Management (iSage)

Start date: August 28, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the benefits of using the iSage app for basal insulin titration and support. By doing this study the investigators hope to learn whether the app improves the participant's ability to follow his/her healthcare provider's instructions to adjust his/her insulin doses.

NCT ID: NCT03700801 Not yet recruiting - Clinical trials for Type 2 Diabetes Mellitus

Study of Efficacy, Weight Control, and Safety in Newly-diagnosed Type 2 Diabetes With Different Antidiabetic Therapy

Start date: October 2018
Phase: Phase 4
Study type: Interventional

Study Hypothesis´╝ÜCompared with premixed insulin, triple oral combination therapy has similar hypoglycemic effect, better weight control and lower incidence of hypoglycemia. Main objective: Comparing whether the hypoglycemic efficacy of the triple oral combination therapy is not inferior than that of the premixed insulin in the treatment of newly-diagnosed type 2 diabetes. Secondary objective: Comparing the effects on body weight and the risk of inducing hypoglycemia between triple oral combination therapy and premixed insulin, and exploring the effects of these two therapies on weight control and safety. Primary Study Endpoint: The absolute change in baseline of HAb1c after 12 weeks. Secondary Study Endpoint: fasting blood glucose, 2-hour postprandial blood glucose, fasting C-peptide, 2-hour postprandial C-peptide, body weight, proportion of patients with hypoglycemia, etc.

NCT ID: NCT03686917 Not yet recruiting - Clinical trials for Type 2 Diabetes Mellitus

Validation of a CREATION Health Assessment Tool for Patients in a Diabetic Outpatient Population

CHAT-P
Start date: October 1, 2018
Phase:
Study type: Observational

Participants will complete a survey before an educational session, during the "break" of an educational session, or after the session.

NCT ID: NCT03684642 Not yet recruiting - Clinical trials for Type 2 Diabetes Mellitus

Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin

AMPLITUDE-D
Start date: September 27, 2018
Phase: Phase 3
Study type: Interventional

Primary Objective: To demonstrate the noninferiority of once weekly injection of efpeglenatide in comparison to once weekly injection of dulaglutide on glycated hemoglobin (HbA1c) change in participants with Type 2 diabetes mellitus (T2DM) inadequately controlled with metformin Secondary Objectives: - To demonstrate the superiority of once weekly injection of efpeglenatide with once weekly injection of dulaglutide on glycemic control - To demonstrate the superiority of once weekly injection of efpeglenatide with once weekly injection of dulaglutide on body weight - To evaluate the safety of once weekly injection of efpeglenatide and once weekly injection of dulaglutide

NCT ID: NCT03675464 Not yet recruiting - Obesity Clinical Trials

Study of Human Adipose Tissue (LOSHAT)

LOSHAT
Start date: September 20, 2018
Phase:
Study type: Observational

The investigators will study the influence of initial fat cell size/number and adipose function (in particular lipolysis) on weight development over very long time periods (years). By comparing investigations of fat biopsies or blood samples obtained at baseline, the investigators will determine the association between adipose morphology/function and changes in weight or development of metabolic complications (e.g. metabolic syndrome, glucose intolerance, type 2 diabetes, dyslipidemia and hypertension).

NCT ID: NCT03670641 Not yet recruiting - Clinical trials for Type 2 Diabetes Mellitus

Remission Through Early Monitored Insulin Therapy - Duration Month

REMIT-DM
Start date: October 1, 2018
Phase: Phase 4
Study type: Interventional

REMIT-DM is a feasibility pilot study where participants will be recruited soon after their diagnosis of type 2 diabetes to be placed immediately on insulin therapy for maximum of four weeks with titrations of insulin guided by glucose levels and trends provided by a continuous glucose monitor (CGM), with the purpose of achieving diabetes remission.